Results 191 to 200 of about 333,809 (260)
Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience. [PDF]
Han M, Yoon SE, Cho J, Kim SJ, Kim WS.
europepmc +1 more source
ABSTRACT Objective This single‐center retrospective cohort study evaluated whether, among patients with stage IV cancer who participated in a pragmatic “alkalization therapy”—defined as a low potential renal acid load diet plus oral sodium bicarbonate and/or potassium/sodium citrate—urinary pH was associated with long‐term survival.
Shion Kachi +5 more
wiley +1 more source
Pediatric extranasal, EBV-negative, extranodal natural killer/T-cell lymphoma; case report. [PDF]
Gallant R, Khan O.
europepmc +1 more source
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara +20 more
wiley +1 more source
A rare collision tumor of lymphoepithelioma-like carcinoma and t-cell lymphoma: a case report. [PDF]
Zhu M, Zhang J.
europepmc +1 more source
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian +12 more
wiley +1 more source
Case Report: Probable CLIPPERS in a patient with cutaneous T-cell lymphoma in remission: 5-year follow-up. [PDF]
Hong K +6 more
europepmc +1 more source
Marketing authorizations for oncology drugs are often based on single‐arm trials (SATs), and real‐world data‐based external comparator cohorts (ECCs) are increasingly explored to contextualize results. In retrospective studies, comparators may be identified by time of diagnosis but included based on time of relapse; such sampling strategies can ...
Mikkel Runason Simonsen +6 more
wiley +1 more source
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial. [PDF]
Makita S +18 more
europepmc +1 more source
Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian +5 more
wiley +1 more source

